Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma
Author Information
Author(s): David Olmos, Ana Sofia Martins, Robin L. Jones, Salma Alam, Michelle Scurr, Ian R. Judson
Primary Institution: The Royal Marsden NHS Foundation Trust
Hypothesis
The insulin-like growth factor 1 receptor (IGF-1R) is a potential therapeutic target in Ewing's sarcoma.
Conclusion
IGF-1R inhibitors show promise in treating Ewing's sarcoma, but not all patients benefit, highlighting the need for predictive markers.
Supporting Evidence
- Approximately 30% of patients with Ewing's sarcoma will relapse and die from the disease.
- Initial Phase I studies of IGF-1R monoclonal antibodies showed several clinical responses.
- About a fourth of patients may benefit from IGF-1R monoclonal antibodies as single therapy.
Takeaway
Doctors are trying to use a special target in cancer cells called IGF-1R to help kids with a type of bone cancer called Ewing's sarcoma, but it doesn't work for everyone.
Methodology
The study reviewed preclinical and clinical data on IGF-1R inhibitors in Ewing's sarcoma.
Potential Biases
Potential bias in patient selection and response evaluation.
Limitations
The clinical trials had varying results, and not all patients responded to the treatment.
Participant Demographics
The study included patients with Ewing's sarcoma, primarily adolescents and young adults.
Statistical Information
P-Value
p<0.001
Confidence Interval
CI-95% 1.8–2.1
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website